Literature DB >> 23595974

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.

E Carmina1, A M Campagna, R A Lobo.   

Abstract

STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY
DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Thirty-five age-matched controls and another 35 age-matched controls in their 40s, 20 years later. Longitudinal measurements of body mass index (BMI), waist circumference, fasting serum steroids, glucose, insulin, lipids, prevalence of metabolic syndrome and ovulatory status. MAIN RESULTS AND THE ROLE OF CHANCE: After 20 years, in the entire group, waist circumference increased as did glucose, total cholesterol (C), high-density lipoprotein-C (HDL-C), LDL-C and non-HDL-C. The prevalence of metabolic syndrome was 7% at the beginning and 6% at the end. Fifty-one women with PCOS were found to be ovulatory and 67 remained anovulatory after 20 years. Anovulatory women had higher insulin, lower QUICKI and higher total C, LDL-C, non-HDL-C and lower HDL-C. In ovulatory women there were no alterations in lipids or glucose and minor changes in insulin and QUICKI compared with controls. None of the parameters were influenced by BMI or waist circumference. LIMITATIONS, REASONS FOR CAUTION: Inability to follow controls for 20 years. Associations observed between ovulatory function and lowered cardiovascular and metabolic risks cannot imply cause and effect. WIDER IMPLICATIONS OF THE
FINDINGS: Phenotypic variability, particularly ovulatory function, in women diagnosed to have PCOS appears to influence cardiovascular and metabolic risks. It is unclear if these data pertain to other populations and ethnicities of women. STUDY FUNDING/COMPETING INTERESTS: Self-funded; no conflicts of interest.

Entities:  

Keywords:  PCOS; aging; insulin; lipids; ovulation

Mesh:

Substances:

Year:  2013        PMID: 23595974     DOI: 10.1093/humrep/det119

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  17 in total

1.  Increased androgen, anti-Müllerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype?

Authors:  Lindsey A Sjaarda; Sunni L Mumford; Kerri Kissell; Karen C Schliep; Ahmad O Hammoud; Neil J Perkins; Jennifer Weck; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2014-02-28       Impact factor: 5.958

2.  Free radical scavenging window of infertile patients with polycystic ovary syndrome: correlation with embryo quality.

Authors:  Bo Huang; Zhou Li; Xinling Ren; Jihui Ai; Lixia Zhu; Lei Jin
Journal:  Front Med       Date:  2017-05-05       Impact factor: 4.592

3.  Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome.

Authors:  Zelija Velija-Asimi; Azra Burekovic; Tanja Dujic; Amela Dizdarevic-Bostandzic; Sabina Semiz
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

4.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 5.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 6.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

7.  Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause.

Authors:  Corrine K Welt; Enrico Carmina
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

8.  Predictors of subclinical cardiovascular disease in women with polycystic ovary syndrome: interrelationship of dyslipidemia and arterial blood pressure.

Authors:  Djuro Macut; Marina Bačević; Ivana Božić-Antić; Jelica Bjekić-Macut; Milorad Čivčić; Snježana Erceg; Danijela Vojnović Milutinović; Olivera Stanojlović; Zoran Andrić; Biljana Kastratović-Kotlica; Tijana Šukilović
Journal:  Int J Endocrinol       Date:  2015-03-24       Impact factor: 3.257

9.  Menstrual Cycle Irregularity and Metabolic Disorders: A Population-Based Prospective Study.

Authors:  Marzieh Rostami Dovom; Fahimeh Ramezani Tehrani; Shirin Djalalinia; Leila Cheraghi; Samira Behboudi Gandavani; Fereidoun Azizi
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

10.  Polycystic Ovarian Syndrome and Menopause in Forty Plus Women.

Authors:  Sudhaa Sharma; Neha Mahajan
Journal:  J Midlife Health       Date:  2021-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.